Similarly, For pancreatic neuroendocrine tumors (Pan-NETs), the ESMO guidelines state that patients with highly functional Pan-NETs with a high tumor burden may benefit from tumor debulking surgery (e.g., insulinomas, vasoactive intestinal peptide (VIP)omas), and surgery is typically recommended for this indication. This evidence concerns the gene VIP and pancreatic insulinoma.